1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65C6827B1B0186DB885256DBB0065C130
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/winning-in-licensing-strategies-in-developing-criteria-for-compound-evaluations?opendocument
18
19
20
21
22
23
24/bestp/domrep.nsf
25DB




Products & Services New Product Development New Product Planning

Winning In-Licensing Strategies in Developing Criteria for Compound Evaluations

ID: 4497


Features:

Graphics


Words: 2,547


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
This nine-page document examines three critical approaches to developing strategy for in-licensing organizations. Business development executives at leading pharmaceutical companies detail how they shape strategies for evaluating potential product partnering deals on the basis of: 1) a focused vs. opportunistic approach, 2) risk tolerance and 3) a growth vs. filling gaps in portfolio approach. The information in these topical areas will inform in-licensing and business development decision-makers how their competitors base their own strategic plans for pursuing in-licensing opportunities.


Within the three strategy areas, specific topic areas include:

  • Degree of strategy decision centralization
  • Therapeutic or target area basis for focused approach
  • Decision-making processes for filtering large numbers of compounds
  • Connection between risk tolerance and stages in which deals are made
  • Value of utility vs. clinical trial results

This document originated from a Best Practices, LLC consulting project.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Health Care; Chemical


Companies Profiled:
AstraZeneca; Sanofi-aventis; Roche; Johnson & Johnson; Novartis; GlaxoSmithKline; Genentech; Bristol-Myers Squibb

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.